Emerging opportunistic yeast infections

Area of Science:

• Medical Mycology
• Infectious Diseases
• Immunocompromised Host Research

Background:

• The rising population of immunosuppressed patients leads to more frequent invasive fungal infections (IFIs).
• Non-albicans Candida species, such as Candida glabrata and Candida krusei, are increasingly diagnosed and may exhibit azole resistance.
• Unusual yeasts like Trichosporon, Rhodotorula, and non-neoformans Cryptococci are emerging as significant pathogens in specific patient groups.

Purpose of the Study:

• To highlight the growing threat of IFIs caused by unusual yeasts in immunocompromised individuals.
• To discuss the diagnostic challenges and suboptimal treatment outcomes associated with these emerging pathogens.
• To underscore the importance of host immune status in determining susceptibility to specific IFIs.

Main Methods:

• Review of current literature on invasive fungal infections caused by uncommon yeasts.
• Analysis of species prevalence, resistance patterns, and clinical outcomes.
• Discussion of diagnostic modalities, including traditional cultures and adjunctive serum (1,3)-β-D-glucan testing.

Main Results:

• Increasing incidence of non-albicans Candida, Trichosporon, Rhodotorula, and other rare yeasts causing IFIs.
• Documented resistance to standard antifungal therapies (e.g., azoles, amphotericin B, echinocandins) in several species.
• Identification of specific risk factors, including hematological malignancies, advanced HIV infection, and transplantation.

Conclusions:

• Invasive infections by rare yeasts represent a growing clinical challenge, particularly in severely immunocompromised patients.
• Current diagnostic methods are often insufficient, and treatment strategies require optimization.
• Further research is crucial for improved diagnosis and management of IFIs caused by emerging fungal pathogens.